Physician profile
David Lustig
NPI 1316971252
$1,524.36
in general payments reported to CMS, 2019-2025
24 companies · $20.72 in 2025
The $20.72 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $101 · 2021: $292 · 2022: $595 · 2023: $142 · 2024: $191 · 2025: $20.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $353.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $202.93 | 2022-2024 | |
| Amgen INC. | $172.73 | 2021-2022 | |
| Ucb, INC. | $158.87 | 2021-2024 | Nayzilam |
| Teva Pharmaceuticals USA, INC. | $139.23 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.49 | 2022 | |
| Scilex Pharmaceuticals INC. | $89.73 | 2019-2022 | |
| Pfizer INC. | $86.97 | 2023-2024 | |
| Avanir Pharmaceuticals, INC. | $86.69 | 2021-2022 | |
| Lundbeck LLC | $68.26 | 2022-2024 | Vyepti |
| Akcea Therapeutics, INC. | $62.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $59.24 | 2019-2023 | |
| Allergan, INC. | $41.92 | 2019-2021 | |
| Medtronic, INC. | $37.99 | 2024-2025 | Inceptiv |
| Merz Pharmaceuticals, LLC | $35.94 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $23.74 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $20.98 | 2023 | Vyvgart |
| Sentynl Therapeutics, INC. | $17.59 | 2019 | |
| Saluda Medical Americas, INC. | $16.42 | 2024 | Evoke |
| Spineology INC. | $15.92 | 2022 | |
| Genzyme Corporation | $15.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.28 | 2021 | |
| Zyla Life Sciences, INC. | $12.30 | 2019 | |
| Lilly USA, LLC | $11.73 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lustig listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.